Business Wire

Imperva Data Security Fabric Provides Bold New Approach to Securing All Data in Multicloud and Hybrid Environments

5.4.2022 15:00:00 EEST | Business Wire | Press release

Share

Imperva, Inc., (@Imperva) the comprehensive digital security leader, introduces the Imperva Data Security Fabric (DSF) to modernize and simplify data governance, security, and workflow management for all data across multicloud and hybrid environments. Imperva DSF standardizes data security controls across enterprise environments to provide full visibility of what is happening across all file stores and assets, on-premises, and across clouds. Its flexible architecture supports a wide range of data repositories, ensuring security policies are applied consistently everywhere.

Imperva DSF integrates Imperva Sonar and a deep portfolio of industry-leading and mission critical Imperva Data Security products and technologies. Customers are already using Imperva DSF capabilities to secure data in hundreds of data stores across leading cloud providers. These capabilities provide access to thousands of automation and response integrations to streamline visibility, create specific rules for managing data risk, and leverage a mix of security tools supporting those platforms.

Imperva DSF makes it easier for customers to understand and mitigate data risk at every step of their security journey across structured, semi-structured, and unstructured data. According to Gartner, “by 2024, larger enterprises will triple the unstructured data stored as file or object storage on-premises, at the edge or in the public cloud, compared with 2020. This massive growth in unstructured data demands better protection against threats such as ransomware.1” Imperva DSF can discover and classify more than 350 unique file formats, including the most widely used formats by Adobe, Google, Microsoft, and many others. Imperva DSF protects a customer’s multicloud and hybrid environments and provides visibility through a single service that can run anywhere within that environment. Imperva DSF provides a holistic view that makes it easier for customers to quickly identify and secure sensitive information across their entire protected environment.

Across a broad range of areas including policy compliance, compromised credentials, unintentional misuse, and malicious threats to sensitive data, organizations in all industries around the world are asking for our help to protect their data. They need broad but centralized control and automation for a more comprehensive view of risk posture, faster insights to accelerate response times, and reduced cost of ownership,” says Dan Neault, SVP and GM, Data Security, Imperva. “Imperva Data Security Fabric enables organizations to safeguard their sensitive data while ensuring data security, compliance, and privacy, and managing digital risk while confidently moving strategic data to the cloud.”

Imperva DSF and its unique automation capabilities for agent and agentless deployments makes it simpler and lower cost for customers to scale data governance and protection anywhere. "After going through a painful situation with another Data Activity Monitoring solution, we went with Imperva because we needed to deliver something quickly for compliance reasons. Imperva offered us a more efficient agent-based solution in terms of cost, management and a lot less complexity. You get to do everything in a single place,” says Diego Laverde, CISO of Banco Popular Dominicano. “It went into production seamlessly, the business didn’t even realize that it had happened, and it worked as it should.”

Through the Imperva Technology Alliance Program (TAP), Imperva DSF has built-in integrations with the world’s leading hyperscalers (e.g., Amazon Web Services™, Microsoft® Azure®, Google Cloud™, etc.), database vendors (e.g., Microsoft®, MongoDB® Atlas, Oracle DBMS, Snowflake™, etc.), and workflow managers (e.g., Atlassian, ServiceNow™, etc.). Imperva DSF opens up new partner-builder innovation opportunities to provide customers additional capabilities and simplify their orchestration. Imperva TAP is pleased to welcome Mage™ (formerly Mentis), a data masking alternative to Imperva DSF built-in capabilities to help customers secure structured and unstructured data throughout the development lifecycle.

“We are excited about the possibilities Imperva DSF enables for mutual customers and the partner ecosystem,” says Rajesh Parthasarathy, CEO of Mage. “Our technology alliance with Imperva provides organizations with an analyst-recognized integrated masking solution for all data types supported by the Imperva DSF.”

Imperva Data Security Fabric includes:

  • Data Activity Monitoring: mitigate malicious insiders and external threats by detecting changes, auditing activities for compliance, and blocking or alerting on policy violations.
  • Data Risk Analytics: automate detection of non-compliant, risky, or malicious data access behavior across data stores.
  • Data Governance: discover and classify sensitive data residing in structured, semi-structured, and unstructured data types, to operationalize security control policies.
  • Data Access Control: control user rights to sensitive data, including detecting overly-broad data access in the cloud or on-premises.
  • Data Masking: transform data so it is either unreadable or de-identified, allowing processing to happen in compliance.

Additional Information:

GARTNER is registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved

About Imperva

Imperva is the comprehensive digital security leader on a mission to help organizations protect their data and all paths to it. Only Imperva protects all digital experiences, from business logic to APIs, microservices, and the data layer, and from vulnerable, legacy environments to cloud-first organizations. Customers around the world trust Imperva to protect their applications, data, and websites from cyber attacks. With an integrated approach combining edge, application security, and data security, Imperva protects companies ranging from cloud-native start-ups to global multi-nationals with hybrid infrastructure. Imperva Threat Research and our global intelligence community keep Imperva ahead of the threat landscape and seamlessly integrate the latest security, privacy, and compliance expertise into our solutions.

© 2022 Imperva, Inc. All rights reserved. Imperva is a registered trademark of Imperva, Inc.

1Gartner Hype Cycle for Storage and Data Protection Technologies, Julie Palmer, 22 July 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Erik Kingham
erik.kingham@imperva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye